Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Show more...
FAQ
Ernexa Therapeutics 今天的股價是多少?▼
ERNA.BOATS 目前價格為 $11.46 USD,過去 24 小時上漲了 +5.04%。在圖表上更密切關注 Ernexa Therapeutics 股價表現。
Ernexa Therapeutics 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Ernexa Therapeutics 的股票以代號 ERNA.BOATS 進行交易。
Ernexa Therapeutics 下一次財報日期是什麼時候?▼
Ernexa Therapeutics 將於 August 17, 2026 公布下一次財報。
Ernexa Therapeutics 有多少名員工?▼
截至 May 26, 2026,公司共有 6 名員工。
Ernexa Therapeutics 位於哪個產業?▼
Ernexa Therapeutics從事於Other產業。
Ernexa Therapeutics 何時完成拆股?▼
Ernexa Therapeutics 上次拆股發生於 May 04, 2026,比例為 1:25。
Ernexa Therapeutics 的總部在哪裡?▼
Ernexa Therapeutics 的總部位於 美國 的 Cambridge。